Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 7/20 | 0.59 |
| ▸ | TGFBR1 | P36897 | 18/20 | 0.51 |
| ▸ | TGFBR2 | P37173 | 7/20 | 0.48 |
| ▸ | MAP3K20 | Q9NYL2 | 7/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18114998 | 0.89 | THRB (0.52) | THRBTGFBR1TGFBR2MAP3K20MAPK14 | |
| SCHEMBL18115117 | 0.88 | TGFBR1 (0.57) | THRBTGFBR1TGFBR2MAP3K20MAPK14 | |
| SCHEMBL18115007 | 0.88 | THRB (0.51) | THRBTGFBR1TGFBR2MAP3K20MAPK14 | |
| SCHEMBL18115095 | 0.88 | THRB (0.51) | THRBTGFBR1TGFBR2MAP3K20MAPK14 | |
| SCHEMBL29529491 | 0.88 | THRB (0.51) | THRBTGFBR1TGFBR2MAP3K20MAPK14 | |
| SCHEMBL29530607 | 0.88 | THRB (0.51) | THRBTGFBR1TGFBR2MAP3K20MAPK14 | |
| SCHEMBL18115073 | 0.86 | THRB (0.60) | THRBTGFBR1TGFBR2MAP3K20MAPK14 | |
| SCHEMBL29908622 | 0.85 | TGFBR1 (0.52) | THRBTGFBR1TGFBR2MAP3K20CYP2D6 | |
| SCHEMBL18114952 | 0.85 | TGFBR1 (0.52) | THRBTGFBR1TGFBR2MAP3K20CYP2D6 | |
| SCHEMBL18115036 | 0.85 | TGFBR1 (0.47) | THRBTGFBR1TGFBR2MAP3K20MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3277673-B1 | TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-05-04 | — | — | EP | claimed |
| US-10822337-B2 | TGF-β inhibitorC | RIGEL PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | claimed |
| US-20180086764-A1 | TGF-ß Inhibitors | MIDCAP FINANCIAL TRUST | 2018-03-29 | — | — | US | claimed |
| EP-3277673-A1 | TGF-BETA INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2018-02-07 | — | — | EP | claimed |
| WO-2016160881-A1 | TGF-β INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | claimed |
| US-12227508-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20230123591-A1 | TGF-ß INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230123591-A1 | TGF-ß INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-11466018-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3277673-B1 | TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3277673-B1 | TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20210130361-A1 | TGF-ß INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210130361-A1 | TGF-ß INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-10822337-B2 | TGF-β inhibitorC | RIGEL PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10822337-B2 | TGF-β inhibitorC | RIGEL PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20180086764-A1 | TGF-ß Inhibitors | MIDCAP FINANCIAL TRUST | 2018-03-29 | — | — | US | disclosed |
| US-20180086764-A1 | TGF-ß Inhibitors | MIDCAP FINANCIAL TRUST | 2018-03-29 | — | — | US | disclosed |
| US-20180086764-A1 | TGF-ß Inhibitors | MIDCAP FINANCIAL TRUST | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227508-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | THRB 102/4885TGFBR1 1/4885TGFBR2 2/4885 |
| US-10822337-B2 | TGF-β inhibitorC | TGFBR1, TGFBR2, TGFB1 | THRB 193/4885TGFBR1 1/4885TGFBR2 2/4885 |
| US-11466018-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | THRB 102/4885TGFBR1 1/4885TGFBR2 2/4885 |
| US-20210130361-A1 | TGF-ß INHIBITORS | TGFBR1, TGFBR2, TGFB1 | THRB 86/4885TGFBR1 1/4885TGFBR2 2/4885 |
| US-20180086764-A1 | TGF-ß Inhibitors | TGFBR1, TGFBR2, TGFB1 | THRB 86/4885TGFBR1 1/4885TGFBR2 2/4885 |
| US-20230123591-A1 | TGF-ß INHIBITORS | TGFBR1, TGFBR2, TGFB1 | THRB 86/4885TGFBR1 1/4885TGFBR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.